Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IESC | PRESS-RELEASE | bullish | 6/10 | IES Holdings reported Q3 2026 EPS of $7.57, a 34.9% beat vs. consensus of $5.61, with no revenue figure disclosed. The s | Aug 14, 2026 |
| GALT | PRESS-RELEASE | bullish | 8/10 | Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headli | Aug 14, 2026 |
| DY | PRESS-RELEASE | neutral | 1/10 | Dycom Industries Inc announced it will host a conference call on August 26, 2026 to discuss its fiscal Q2 2027 results. | Aug 14, 2026 |
| BTQ | PRESS-RELEASE | neutral | 3/10 | BTQ Technologies provided a Q2 2026 corporate update highlighting commercial progress across its four business lines (QC | Aug 14, 2026 |
| JKS | PRESS-RELEASE | neutral | 1/10 | JinkoSolar Holding Co., Ltd. announced it will report its Q2 2026 results on August 26, 2026. | Aug 14, 2026 |
| HURA | PRESS-RELEASE | neutral | 3/10 | TuHURA Biosciences reported Q2 2026 financial results with no revenue or EPS, as the company remains pre-revenue. Cash s | Aug 14, 2026 |
| LNTH | PRESS-RELEASE | bullish | 7/10 | Lantheus received FDA approval for TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for evaluating Alzheimer's di | Aug 14, 2026 |
| JG | PRESS-RELEASE | bullish | 5/10 | Aurora Mobile signed a three-year MoU with Exabytes, Southeast Asia's AI-driven digital solutions provider, to explore i | Aug 14, 2026 |
| JJSF | PRESS-RELEASE | neutral | 2/10 | J & J Snack Foods Corp. declared a quarterly cash dividend of $0.80 per share, payable on October 6, 2026, to shareholde | Aug 14, 2026 |
| OTLK | PRESS-RELEASE | mixed | 7/10 | Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missing the consensus esti | Aug 14, 2026 |
| UTSI | PRESS-RELEASE | bearish | 6/10 | UTStarcom reported a sharp 26% YoY revenue decline to $3.4M for 1H 2026, with gross margin swinging to a loss of $0.5M. | Aug 14, 2026 |
| RNTX | PRESS-RELEASE | bullish | 6/10 | Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating consensus of -$0.27 by 63%, driven by lower operating exp | Aug 14, 2026 |
| ANL | PRESS-RELEASE | bullish | 6/10 | Adlai Nortye reported H1 2026 results with revenue of $13.1M (from nil) from an AN9025 license agreement, net loss narro | Aug 14, 2026 |
| PWCM | PRESS-RELEASE | bearish | 6/10 | PowerCompute (PWCM) reported Q2 2026 revenue of $2.1M (+9.8% YoY) but missed consensus of $2.3M, and EPS of -$5.26 misse | Aug 14, 2026 |
| QNTM | PRESS-RELEASE | bullish | 7/10 | Quantum BioPharma reported Q2 2026 EPS of -$0.71, a 21% miss vs consensus of -$0.59, but the headline event is the FDA c | Aug 14, 2026 |
| TMS | PRESS-RELEASE | mixed | 5/10 | Teamshares reported Q2 2026 revenue of $148.7M, missing consensus of $152.7M by 2.6%, while GAAP diluted EPS of $0.16 be | Aug 14, 2026 |
| NMRA | PRESS-RELEASE | neutral | 4/10 | Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalen | Aug 14, 2026 |
| TVRD | PRESS-RELEASE | mixed | 5/10 | Tvardi Therapeutics reported Q2 2026 EPS of -$0.73, a 15.6% miss vs consensus of -$0.63, with no revenue. Pipeline progr | Aug 14, 2026 |
| JOYY | PRESS-RELEASE | neutral | 1/10 | JOYY Inc. announced it will report its Q2 2026 results on August 25, 2026. | Aug 14, 2026 |
| ACXP | PRESS-RELEASE | mixed | 5/10 | Acurx Pharmaceuticals reported Q2 2026 EPS of -$0.53, a 26% miss versus the $0.42 consensus, reflecting higher R&D spend | Aug 14, 2026 |
| FATE | PRESS-RELEASE | bullish | 5/10 | Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for | Aug 14, 2026 |
| EVGN | PRESS-RELEASE | neutral | 1/10 | Evogene announced it will host a conference call on August 18, 2026 to discuss its upcoming quarterly results. | Aug 14, 2026 |
| ORI | PRESS-RELEASE | neutral | 2/10 | Old Republic International declared a regular quarterly dividend of $0.315 per share, payable September 15, 2026. The pr | Aug 14, 2026 |
| HDL | PRESS-RELEASE | neutral | 1/10 | SUPER HI INTERNATIONAL HOLDING LTD. announced it will report its Q2 2026 results on August 26, 2026. | Aug 14, 2026 |
| RLX | PRESS-RELEASE | neutral | 4/10 | RLX Technology reported Q2 2026 revenue of RMB1,010.5M (US$148.9M), up 14.8% YoY, driven by international expansion and | Aug 14, 2026 |
| SFL | PRESS-RELEASE | neutral | 1/10 | SFL Corporation announced it will report its Q2 2026 results on August 26, 2026. | Aug 14, 2026 |
| IMXI | PRESS-RELEASE | bearish | 6/10 | Western Union's acquisition of Intermex received NYDFS approval but the California DFPI suspended its previously granted | Aug 14, 2026 |
| ZNTL | PRESS-RELEASE | bearish | 6/10 | Zentalis Pharmaceuticals priced an underwritten public offering of 23 million shares at $3.50 per share, expecting ~$80. | Aug 13, 2026 |
| RCMT | PRESS-RELEASE | bullish | 7/10 | RCM Technologies reported Q2 2026 revenue of $93.8M (+20% YoY), beating consensus of $82.8M, but GAAP EPS of $0.68 misse | Aug 13, 2026 |
| SNSC | PRESS-RELEASE | neutral | 5/10 | SunScout Holding Limited closed its IPO of 3,100,000 Class A ordinary shares at $5.00 per share, raising $15.5 million i | Aug 13, 2026 |